Optimal scheduling of cancer surgery and adjuvant therapy

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1099546

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer surgery is the most effective single modality for curing patients. Unfortunately, 50% of patients will relapse after surgery due to metastases and require further therapy. Immunotherapies such as Ipilimumab/Nivolumab have been revolutionary in causing long term tumour regression and potential cures in advanced cancers. We have preliminary data showing immunotherapies given before surgery is more effective in preventing metastases and we aim to understand the reason for its effectiveness.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Project Grants

Funding Amount: $667,008.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody cancer therapy | breast cancer metastases | oncology | renal cell carcinoma | surgery

Related Links

ACN 633 798 857